REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights
REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on May 5, 2021 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2021, along with recent operational highlights. Investors can join the call by dialing (855) 422-8964 or (210) 229-8819 for international access, with the passcode 7044809. A live or recorded webcast will also be available on their website for about 30 days after the call. REGENXBIO focuses on gene therapy using its proprietary NAV® Technology Platform with over 100 AAV vectors.
- Announcement of a conference call to discuss financial results and operational highlights may indicate transparency and shareholder engagement.
- None.
ROCKVILLE, Md., April 28, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, May 5, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2021, and recent operational highlights.
To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7044809. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-may-5-to-discuss-first-quarter-2021-financial-results-and-recent-operational-highlights-301279354.html
SOURCE REGENXBIO Inc.
FAQ
When is REGENXBIO's conference call to discuss Q1 2021 results?
How can I access REGENXBIO's conference call?
What will REGENXBIO discuss during the May 5, 2021 conference call?
Where can I find the recorded webcast of REGENXBIO's conference call?
